Principal Financial Group Inc Jounce Therapeutics, Inc. Transaction History

Principal Financial Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	SELL	$2.73 - $4.92 $33,314 - $60,038	-12,203 Reduced 48.78%	12,811 $30,000
Q2 2022 Aug 10, 2022	BUY	$2.8 - $7.67 $18,594 - $50,936	6,641 Added 36.15%	25,014 $76,000
Q1 2022 May 09, 2022	SELL	$6.01 - $8.54 $56,758 - $80,651	-9,444 Reduced 33.95%	18,373 $125,000
Q4 2021 Feb 09, 2022	SELL	$7.11 - $9.64 $129,423 - $175,476	-18,203 Reduced 39.55%	27,817 $232,000
Q3 2021 Nov 09, 2021	SELL	$5.04 - $8.73 $8,749 - $15,155	-1,736 Reduced 3.64%	46,020 $342,000
Q2 2021 Aug 10, 2021	BUY	$6.58 - $10.66 $70,333 - $113,944	10,689 Added 28.84%	47,756 $324,000
Q1 2021 May 10, 2021	BUY	$6.73 - $13.87 $18,810 - $38,766	2,795 Added 8.16%	37,067 $381,000
Q4 2020 Feb 08, 2021	BUY	$6.37 - $10.33 $14,886 - $24,141	2,337 Added 7.32%	34,272 $240,000
Q3 2020 Nov 06, 2020	BUY	$4.58 - $10.95 $69,263 - $165,596	15,123 Added 89.95%	31,935 $260,000
Q2 2020 Aug 05, 2020	BUY	$4.17 - $7.58 $70,106 - $127,434	16,812 New	16,812 $116,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.